Skip to content
HowShorted

Aquestive Therapeutics, Inc. short interest in 2023

In 2023, Aquestive Therapeutics, Inc.'s disclosed short interest ran from 3.01% of shares outstanding on 13 Jan 2023 to 3.07% on 29 Dec 2023, a change of +0.06 percentage points. The year's high was 3.95% on 15 Jun 2023 and its low 2.81% on 30 Nov 2023, averaging 3.37% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 10.50 days on 31 Aug 2023. Full history: Aquestive Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Aquestive Therapeutics, Inc. in 2023

2023 in figures

Start of year
3.01% (13 Jan 2023)
End of year
3.07% (29 Dec 2023)
Change
+0.06 pp
High
3.95% (15 Jun 2023)
Low
2.81% (30 Nov 2023)
Average
3.37%
Highest days to cover
10.50 (31 Aug 2023)
SEC filings marked
8

Every report in 2023

Aquestive Therapeutics, Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 20233.01%6.18
31 Jan 20233.42%9.51
15 Feb 20233.54%5.97
28 Feb 20233.74%7.81
15 Mar 20233.38%4.09results (8-K)
31 Mar 20233.41%7.2310-K filed
14 Apr 20233.44%7.71
28 Apr 20233.29%6.77
15 May 20233.44%1.5410-Q filed, results (8-K)
31 May 20233.49%2.56
15 Jun 20233.95%4.93
30 Jun 20233.10%3.29
14 Jul 20233.46%5.48
31 Jul 20233.66%4.51
15 Aug 20233.51%4.3810-Q filed, results (8-K)
31 Aug 20233.25%10.50
15 Sep 20233.31%8.20
29 Sep 20233.64%7.12
13 Oct 20233.55%10.47
31 Oct 20233.49%10.49
15 Nov 20232.87%9.8810-Q filed, results (8-K)
30 Nov 20232.81%4.27
15 Dec 20233.10%3.04
29 Dec 20233.07%4.58

See also: Aquestive Therapeutics, Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.